Ocular Therapeutix Inc. (OCUL)
| Bid | 6.5 |
| Market Cap | 1.21B |
| Revenue (ttm) | 63.66M |
| Net Income (ttm) | -193.51M |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | -6.21 |
| Forward PE | -7.71 |
| Analyst | Buy |
| Ask | 8.28 |
| Volume | 1,224,354 |
| Avg. Volume (20D) | 1,425,718 |
| Open | 7.17 |
| Previous Close | 7.11 |
| Day's Range | 7.06 - 7.64 |
| 52-Week Range | 4.06 - 11.78 |
| Beta | 1.49 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammati...
Analyst Forecast
According to 10 analyst ratings, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 124.27% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster PotentialOcular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has ...
